← Leaderboards
David Robinson Lynch
Children'S Hospital Of Philadelphia
$10,064,525
Attributed
$12,635,326
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$10,642,531 · 11
FDA$1,992,795 · 1
By mechanism
R01$5,575,666 · 3
U01$3,856,201 · 1
R21$2,746,315 · 6
R56$412,500 · 1
R13$44,644 · 1
Top collaborators
- Ian Alexander Blair5 shared
- Wei-Ting Hwang5 shared
Most similar at Children'S Hospital Of Philadelphia
Same institution · by research overlap
- Beverly S Emanuel$19,569,220
- Deborah A Driscoll$1,414,973
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseEventGlutamatesMediatingAffectNeuronsSiteSerumSynapsesProteinsN-Methyl-D-Aspartate ReceptorsGlutamate ReceptorNovel Therapeutic InterventionNervous System DisorderSynaptic PlasticityBiologicalReceptorPhysiologicalPropertyCell DeathGenesNeuraxisBlood PlateletsFriedreich Ataxia
Grant awards (36)
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia$757,387
U01 · FY2024 · NS
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia$811,272
U01 · FY2023 · NS
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia$752,008
U01 · FY2022 · NS
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia$754,041
U01 · FY2021 · NS
Natural History of Friedreich ataxia in children$399,482
R01 · FY2021 · FD · contact PI
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia$781,493
U01 · FY2020 · NS
Natural History of Friedreich ataxia in children$397,335
R01 · FY2020 · FD · contact PI
Frataxin measurement for clinical trial readiness in Friedreich ataxia$204,600
R21 · FY2020 · TR · contact PI
Natural History of Friedreich ataxia in children$399,062
R01 · FY2019 · FD · contact PI
Frataxin measurement for clinical trial readiness in Friedreich ataxia$267,601
R21 · FY2019 · TR · contact PI
Natural History of Friedreich ataxia in children$397,040
R01 · FY2018 · FD · contact PI
Natural History of Friedreich ataxia in children$399,876
R01 · FY2017 · FD · contact PI
Anti-NMDA receptor antibodies from patients with limbic encephalitis$208,125
R21 · FY2017 · NS · contact PI
Anti-NMDA receptor antibodies from patients with limbic encephalitis$266,750
R21 · FY2016 · NS · contact PI
Ataxia Investigators Meeting 2016: From Basic Science to Clinical Therapeutics$9,644
R13 · FY2016 · NS · contact PI
Metabolic approaches to Friedreich ataxia$205,124
R21 · FY2015 · NS · contact PI
Ataxia Investigators Meeting 2016: From Basic Science to Clinical Therapeutics$35,000
R13 · FY2015 · NS · contact PI
Metabolic approaches to Friedreich ataxia$262,874
R21 · FY2014 · NS · contact PI
Defining the epitope in anti-AMPA receptor encephalitis$202,047
R21 · FY2013 · NS · contact PI
Defining the epitope in anti-AMPA receptor encephalitis$251,250
R21 · FY2012 · NS · contact PI
Nicotinic-glutamatergic Interactions in Axonal Development$209,375
R21 · FY2012 · NS · contact PI
Regulation of NMDA Receptors in Excitotoxicity by Calpain and FYN$365,686
R01 · FY2011 · NS · contact PI
Nicotinic-glutamatergic Interactions in Axonal Development$234,375
R21 · FY2011 · NS · contact PI
Regulation of NMDA Receptors in Excitotoxicity by Calpain and FYN$369,615
R01 · FY2010 · NS · contact PI
Defining the epitope in antiNMDA receptor encephalitis$203,569
R21 · FY2010 · NS · contact PI
Regulation of NMDA Receptors in Excitotoxicity by Calpain and FYN$373,541
R01 · FY2009 · NS · contact PI
Defining the epitope in antiNMDA receptor encephalitis$230,625
R21 · FY2009 · NS · contact PI
Regulation of NMDA Receptors in Excitotoxicity by Calpain and FYN$389,855
R01 · FY2008 · NS · contact PI
Regulation of NMDA Receptors in Excitotoxicity by Calpain and FYN$412,500
R56 · FY2007 · NS · contact PI
Calpain Mediated Cleavage of NR2 in Excitotoxicity$330,076
R01 · FY2006 · NS · contact PI
Calpain Mediated Cleavage of NR2 in Excitotoxicity$339,088
R01 · FY2005 · NS
Calpain Mediated Cleavage of NR2 in Excitotoxicity$340,127
R01 · FY2004 · NS
Calpain Mediated Cleavage of NR2 in Excitotoxicity$351,774
R01 · FY2003 · NS
NMDA RECEPTORS, PROTEIN KINASE C, AND EXCITOTOXICITY$248,194
R01 · FY2002 · NS
NMDA RECEPTORS, PROTEIN KINASE C, AND EXCITOTOXICITY$240,966
R01 · FY2001 · NS
NMDA RECEPTORS, PROTEIN KINASE C, AND EXCITOTOXICITY$233,949
R01 · FY2000 · NS